Home Cart Sign in  
Chemical Structure| 112-27-6 Chemical Structure| 112-27-6

Structure of Triethylene glycol
CAS No.: 112-27-6

Chemical Structure| 112-27-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: PROTAC Linker 25

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Cifone, Matthew T. ; He, YongLe ; Basu, Rajeswari ; Wang, Nan ; Davoodi, Shabnam ; Spagnuolo, Lauren A. , et al.

Abstract: The relationship between drug-target residence time and the post-antibiotic effect (PAE) provides insights into target vulnerability. To probe the vulnerability of bacterial acetyl-CoA carboxylase (ACC), a series of heterobivalent inhibitors were synthesized based on pyridopyrimidine 1 and moiramide B (3) which bind to the biotin carboxylase and carboxyltransferase ACC active sites, resp. The heterobivalent compound 17, which has a linker of 50 Å, was a tight binding inhibitor of Escherichia coli ACC (Kiapp 0.2 nM) and could be displaced from ACC by a combination of both 1 and 3 but not just by 1. In agreement with the prolonged occupancy of ACC resulting from forced proximity binding, the heterobivalent inhibitors produced a PAE in E. coli of 1-4 h in contrast to 1 and 3 in combination or alone, indicating that ACC is a vulnerable target and highlighting the utility of kinetic, time-dependent effects in the drug mechanism of action.

Alternative Products

Product Details of [ 112-27-6 ]

CAS No. :112-27-6
Formula : C6H14O4
M.W : 150.17
SMILES Code : OCCOCCOCCO
Synonyms :
PROTAC Linker 25
MDL No. :MFCD00002880
InChI Key :ZIBGPFATKBEMQZ-UHFFFAOYSA-N
Pubchem ID :8172

Safety of [ 112-27-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Computational Chemistry of [ 112-27-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp3 1.0
Num. rotatable bonds 7
Num. H-bond acceptors 4.0
Num. H-bond donors 2.0
Molar Refractivity 35.45
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

58.92 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.57
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-1.59
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-1.0
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.13
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.07
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.41

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

0.69
Solubility 740.0 mg/ml ; 4.93 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.86
Solubility 1090.0 mg/ml ; 7.27 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.62
Solubility 35.9 mg/ml ; 0.239 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-8.34 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.25

Application In Synthesis of [ 112-27-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 112-27-6 ]
  • Downstream synthetic route of [ 112-27-6 ]

[ 112-27-6 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 107-13-1 ]
  • [ 112-27-6 ]
  • [ 57741-46-5 ]
References: [1] Science China Chemistry, 2010, vol. 53, # 12, p. 2452 - 2460.
[2] Journal of the American Chemical Society, 1943, vol. 65, p. 23,25[3] Journal of the American Chemical Society, 1948, vol. 70, p. 214,215.
[4] Journal of the American Chemical Society, 1943, vol. 65, p. 23,25[5] Journal of the American Chemical Society, 1948, vol. 70, p. 214,215.
[6] Journal of the American Chemical Society, 1943, vol. 65, p. 23,25[7] Journal of the American Chemical Society, 1948, vol. 70, p. 214,215.
[8] Bulletin of the Chemical Society of Japan, 1988, vol. 61, # 7, p. 2443 - 2450.
[9] Patent: US2437905, 1945, , .
[10] Patent: US2372808, 1941, , .
[11] Patent: US2401607, 1944, , .
[12] Patent: US2437905, 1945, , .
[13] Patent: US2372808, 1941, , .
[14] Patent: US2401607, 1944, , .
[15] Patent: US2437905, 1945, , .
[16] Patent: US2372808, 1941, , .
[17] Patent: US2401607, 1944, , .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 112-27-6 ]

Ethers

Chemical Structure| 111-77-3

A124404 [111-77-3]

2-(2-Methoxyethoxy)ethanol

Similarity: 1.00

Chemical Structure| 143-24-8

A139639 [143-24-8]

2,5,8,11,14-Pentaoxapentadecane

Similarity: 1.00

Chemical Structure| 2615-15-8

A195221 [2615-15-8]

3,6,9,12,15-Pentaoxaheptadecane-1,17-diol

Similarity: 1.00

Chemical Structure| 23783-42-8

A240186 [23783-42-8]

2,5,8,11-Tetraoxatridecan-13-ol

Similarity: 1.00

Chemical Structure| 5617-32-3

A449474 [5617-32-3]

3,6,9,12,15,18-Hexaoxaicosane-1,20-diol

Similarity: 1.00

Alcohols

Chemical Structure| 111-77-3

A124404 [111-77-3]

2-(2-Methoxyethoxy)ethanol

Similarity: 1.00

Chemical Structure| 2615-15-8

A195221 [2615-15-8]

3,6,9,12,15-Pentaoxaheptadecane-1,17-diol

Similarity: 1.00

Chemical Structure| 23783-42-8

A240186 [23783-42-8]

2,5,8,11-Tetraoxatridecan-13-ol

Similarity: 1.00

Chemical Structure| 5617-32-3

A449474 [5617-32-3]

3,6,9,12,15,18-Hexaoxaicosane-1,20-diol

Similarity: 1.00

Chemical Structure| 111-46-6

A635658 [111-46-6]

2,2'-Oxybis(ethan-1-ol)

Similarity: 1.00